Medtronic PLC $MDT Holdings Cut by M&G PLC

M&G PLC reduced its stake in Medtronic PLC (NYSE:MDT) by 7.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,842,222 shares of the medical technology company’s stock after selling 230,247 shares during the period. Medtronic accounts for about 1.4% of M&G PLC’s investment portfolio, making the stock its 16th biggest holding. M&G PLC owned about 0.22% of Medtronic worth $270,011,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in MDT. Brighton Jones LLC increased its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC grew its position in Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in shares of Medtronic by 4.5% during the second quarter. Stratos Wealth Partners LTD. now owns 65,856 shares of the medical technology company’s stock valued at $5,741,000 after buying an additional 2,859 shares during the last quarter. Foster & Motley Inc. boosted its position in shares of Medtronic by 9.5% during the second quarter. Foster & Motley Inc. now owns 38,185 shares of the medical technology company’s stock worth $3,329,000 after buying an additional 3,305 shares during the period. Finally, Stanley Laman Group Ltd. grew its holdings in Medtronic by 15.4% in the 2nd quarter. Stanley Laman Group Ltd. now owns 3,620 shares of the medical technology company’s stock worth $316,000 after buying an additional 483 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 1.3%

Shares of NYSE:MDT opened at $99.57 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a market capitalization of $127.65 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.62 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company has a 50 day moving average price of $99.28 and a 200 day moving average price of $96.46.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is currently 76.55%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on MDT shares. Daiwa Securities Group increased their price target on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. UBS Group restated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research report on Wednesday, February 4th. CICC Research began coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Finally, Needham & Company LLC upgraded Medtronic from a “hold” rating to a “buy” rating and set a $121.00 target price for the company in a research report on Monday, February 9th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $111.21.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).